查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1976601

肺炎检测​​市场：依检测类型、技术平台、检体类型、最终用户和通路划分－2026-2032年全球预测

Pneumonia Testing Market by Test Type, Technology Platform, Sample Type, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，肺炎检测市场价值将达到 16.8 亿美元，到 2026 年将成长到 18 亿美元，到 2032 年将达到 27.1 亿美元，复合年增长率为 7.02%。

主要市场统计数据
基准年 2025 16.8亿美元
预计年份：2026年 18亿美元
预测年份 2032 27.1亿美元
复合年增长率 (%) 7.02%

简要概述临床重点、检查室实务和诊断技术创新如何融合，从而重新定义肺炎检测途径。

由于临床需求、技术成熟以及医疗服务模式的变革，肺炎诊断领域正经历快速的重组。临床医生和实验室管理人员越来越关注能够缩短反应时间、提高病原体特异性并实现标靶抗生素治疗的诊断路径。因此，兼具分子水平灵敏度和易用性的诊断方法变得日益重要，而传统的基于培养的方法在复杂病例中仍然发挥着至关重要的作用，能够提供明确的诊断和药敏数据。

分子检测的快速分散化、免疫检测性能的提高以及更聪明的影像整合如何重塑肺炎的诊断和治疗模式。

肺炎诊断领域正经历着一场变革，这主要归因于多种因素的共同作用，包括技术进步、医疗服务模式的变革以及人们对诊断速度和特异性的日益增长的期望。曾经需要中心检查室基础设施的分子诊断平台，如今正以分散式形式提供，帮助临床医生在诊疗过程中做出决策。同时，免疫检测和侧向层析技术的进步提升了分析能力，使其能够在传统实验室之外广泛应用于筛检和监测。

本研究评估了近期关税调整对加强供应链韧性、区域性转移製造地以及调整诊断试剂分销中的策略采购方法的影响。

2025年的关税政策变化为诊断产品和耗材分销领域的相关人员带来了重大的营运和策略考量。进口关税和跨境贸易条件的调整影响了采购决策，促使製造商和经销商重新评估其供应链布局、库存缓衝和区域製造伙伴关係。在许多情况下，先前依赖少数国际供应商的企业已实现供应商多元化，以降低贸易政策波动带来的风险。

策略性细分，详细分析测试类型、技术平台、最终用户工作流程、检体模式和分销管道的复杂性如何决定产品和市场的适用性。

关键的市场细分洞察凸显了产品开发、临床应用和分销策略需要与不同的检测方法和终端用户需求相符。依检测类型划分，市场涵盖培养法、免疫检测法、分子诊断法和放射影像法。在培养法中，细菌和真菌亚种的鑑定对于合理使用抗生素和复杂感染疾病的管理至关重要。免疫检测分为抗体法和抗原法，可用于急性期诊断和血清学监测。分子检测法又可细分为等温扩增法和RT-PCR技术，在速度和分析灵敏度方面各有优劣。放射影像法分为电脑断层扫描和X光检查，分别在急性期评估和长期监测中发挥不同的作用。

从不同地区的比较观点来看，医疗保健基础设施、管理体制和製造能力的差异如何影响肺炎诊断方法的引入和部署。

区域趋势揭示了需求驱动因素、基础设施能力和政策环境的差异，这些差异影响诊断策略和投资重点。在美洲，先进的检测网络以及门诊和社区医疗机构照护现场检测的广泛应用，催生了对快速分子检测和免疫检测解决方案的强劲需求，这些方案有助于合理使用抗生素和优化急救流程。同时，欧洲、中东和非洲的情况更为复杂，既有功能强大的三级医疗中心，也有资源匮乏的医疗机构。这种两极化凸显了模组化平台和扩充性成像解决方案的重要性，这些方案既能部署在不同的医疗环境中，又能满足严格的监管标准。

这项对产业策略的深刻分析揭示了产品模组化、合作伙伴检验和通路多样性如何定义诊断领域的竞争优势。

产业相关人员展现出多元化的策略方针，体现了他们在创新、规模和服务交付方面的不同优先事项。领先的诊断开发公司优先考虑平台模组化，以使其能够在照护现场、中心检查室和参考网路中使用；而其他公司则专注于高度专业化的检测方法，以解决病原体特异性或抗药性检测等特定领域的问题。仪器製造商与临床实验室网路之间的合作日益普遍，以此加速临床检验并将新技术整合到现有工作流程中。

针对不同的临床和分销环境，提出加强互通性、保障区域供应链和商业化的实用建议。

为了将洞察转化为营运优势，产业领导者应专注于推广旨在增强诊断可靠性、加速部署和提升供应链灵活性的各项措施。优先考虑跨平台的互通性和标准化资料格式，以实现检测结果和影像输出与电子健康记录 (EHR) 和临床决策支援工具的互通性整合。这种互通性能够减少临床医生工作流程中的摩擦，并支援下游分析，从而促进品质改进和监测。

透过采用严格的混合调查方法，结合现场临床访谈、技术检验审查和供应链映射，我们获得了基于证据的、可操作的见解。

本分析的调查方法采用混合方法，以获得可靠的三角验证结果。主要研究包括对临床实验室部门主管、医院采购负责人、放射科负责人和照护现场医生进行结构化访谈，以了解营运重点和实际工作流程的限制。此外，还与测试开发人员和生产经理进行了技术咨询，以明确平台功能、法规遵循途径和生产注意事项，从而补充了这些定性见解。

综合分析强调综合诊断策略、供应链韧性以及与多样化临床工作流程的协调一致，从而推动患者疗效的改善。

总之，肺炎诊断生态系统正朝着更一体化、灵活且更具韧性的模式发展，使技术能力与临床需求相契合。分子诊断和免疫检测平台正以支援分散式检查的形式日益普及，而放射诊断技术的创新也持续提升诊断的清晰度和分诊决策的准确性。同时，供应链和政策的发展凸显了多元化采购和区域化生产策略的必要性，以确保关键耗材和平台的可靠供应。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 依检测方法分類的肺炎检测市场

  • 培养试验
    • 细菌培养
    • 真菌培养
  • 免疫检测测定
    • 抗体检测
    • 抗原检测
  • 分子检测
  • 放射影像
    • 电脑断层扫描
    • X射线

第九章：依技术平台分類的肺炎检测市场

  • 数位放射线
  • 等温扩增法
  • 横向流动化验
  • RT-PCR

第十章：依样本类型分類的肺炎检体市场

  • 血
  • 支气管肺泡灌洗液
  • 鼻咽拭子
  • 痰

第十一章 肺炎检测市场：依最终用户划分

  • 居家医疗
  • 医院检查室
    • 院内检查室
    • 外包服务
  • 即时检测
  • 参考检查室

第十二章：肺炎检测市场：依通路划分

  • 离线
  • 在线的

第十三章 肺炎检测市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 肺炎检测市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 肺炎检测市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章：美国肺炎检测市场

第十七章：中国肺炎检测市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Abbott Laboratories
  • Becton Dickinson and Company
  • bioMerieux SA
  • Danaher Corporation
  • Eurofins Scientific SE
  • F. Hoffmann-La Roche Ltd
  • Hain Lifescience GmbH by Bruker Corporation
  • Hologic, Inc.
  • Intec Products, Inc.
  • PerkinElmer, Inc.
  • Qiagen NV
  • Siemens Healthineers AG
  • Thermo Fisher Scientific Inc.
Product Code: MRR-69324464D0F1

The Pneumonia Testing Market was valued at USD 1.68 billion in 2025 and is projected to grow to USD 1.80 billion in 2026, with a CAGR of 7.02%, reaching USD 2.71 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.68 billion
Estimated Year [2026] USD 1.80 billion
Forecast Year [2032] USD 2.71 billion
CAGR (%) 7.02%

A concise overview of how clinical priorities, laboratory practices, and diagnostic innovations are converging to redefine pneumonia testing pathways

The landscape of pneumonia diagnostics is undergoing a rapid reorientation driven by clinical need, technological maturation, and shifting healthcare delivery models. Clinicians and laboratory leaders are increasingly focused on diagnostic pathways that reduce time-to-result, improve pathogen specificity, and enable targeted antimicrobial stewardship. Consequently, diagnostic modalities that integrate molecular sensitivity with operational simplicity have risen in prominence, while traditional culture-based approaches continue to provide essential confirmatory and susceptibility data for complex cases.

At the same time, radiological imaging remains indispensable for disease staging and treatment decisions, particularly where structural complications are suspected. Diagnostic decision-making now frequently involves layered approaches that combine molecular testing, immunoassays, cultures, and imaging to build a comprehensive clinical picture. This hybrid diagnostic paradigm is reinforced by advances in point-of-care platforms that push testing closer to the patient, enabling rapid triage and early intervention.

In summary, the introductory context frames pneumonia testing as a convergent field where laboratory innovation, clinical imperatives, and system-level workflows intersect. Understanding these dynamics is foundational for stakeholders who aim to align product development, laboratory operations, and clinical protocols with evolving standards of care and emerging diagnostic capabilities.

How rapid decentralization of molecular testing, improved immunoassay performance, and smarter imaging integration are reshaping pneumonia diagnostics and care models

The diagnostic landscape for pneumonia is experiencing transformative shifts driven by several converging forces including technological advances, altered care delivery models, and heightened expectations for diagnostic speed and specificity. Molecular platforms that once required centralized laboratory infrastructure are increasingly available in decentralized formats, enabling clinicians to make same-encounter decisions. Meanwhile, immunoassays and lateral flow technologies have improved in analytical performance, supporting broader screening and surveillance use cases outside traditional labs.

Digital radiography and high-resolution imaging continue to benefit from software enhancements and AI-driven interpretation tools that improve lesion detection and standardize reporting. As a result, imaging is no longer purely confirmatory; it contributes actively to diagnostic algorithms when integrated with laboratory data. Another notable shift is the growing importance of sample diversity-nasopharyngeal swabs, sputum, bronchoalveolar lavage, and blood each offer complementary diagnostic yield, prompting laboratories to refine collection and processing workflows accordingly.

Taken together, these shifts are producing more adaptive diagnostic pathways that balance sensitivity, turnaround time, and operational feasibility. Health systems are recalibrating procurement and trial strategies to accommodate integrated testing solutions, while manufacturers prioritize modularity and interoperability. The net effect is a more resilient diagnostic ecosystem capable of addressing routine pneumonia cases and complex, high-acuity presentations alike.

Assessing how recent tariff adjustments have catalyzed supply chain resilience, regional manufacturing shifts, and strategic sourcing adaptations across diagnostics distribution

Tariff policy changes in 2025 have created notable operational and strategic considerations for stakeholders involved in the flow of diagnostic products and supplies. Adjustments to import duties and cross-border trade terms have influenced sourcing decisions, prompting manufacturers and distributors to reassess supply chain footprint, inventory buffers, and regional manufacturing partnerships. In many cases, organizations that previously relied on a limited set of international suppliers diversified their vendor base to mitigate exposure to trade policy volatility.

Consequently, procurement teams updated contracting strategies to incorporate contingency clauses and longer lead-time planning for critical consumables such as reagents, swabs, and cartridges. For some laboratories and device providers, these measures translated into increased emphasis on regional manufacturing and local assembly to reduce tariff impact and secure continuity of supply. At the same time, distributors and channel partners adjusted pricing tables and commercial terms to absorb and redistribute cost fluctuations without disrupting client services.

Overall, the cumulative effect of tariff adjustments in 2025 underscores the importance of supply chain resilience and strategic sourcing. Moving forward, stakeholders are expected to prioritize flexibility in manufacturing partnerships and greater transparency across distribution channels to ensure reliable access to essential diagnostic products while managing cost pressures responsibly.

Strategic segmentation analysis detailing how test type intricacies, technology platforms, end-user workflows, sample modalities, and distribution channels determine product-market fit

Key segmentation insights reveal how product development, clinical adoption, and distribution strategies must align with diverse testing modalities and end-user needs. Based on test type, the market encompasses culture methods, immunoassays, molecular diagnostics, and radiological imaging; within culture, bacterial and fungal subtypes remain critical for antimicrobial stewardship and complex infections, while immunoassay testing divides into antibody and antigen approaches that support both acute diagnosis and serological surveillance. Molecular testing is further differentiated by isothermal amplification and RT-PCR techniques, offering distinct trade-offs between speed and analytical sensitivity. Radiological imaging branches into CT scan and X-ray applications, which serve distinct roles in acuity assessment and longitudinal monitoring.

In terms of technology platform, solutions include digital radiography, isothermal amplification, lateral flow assays, and RT-PCR instruments, each bringing unique operational footprints and training requirements. End-user segmentation spans home care, hospital laboratories, point-of-care testing, and reference laboratories, with hospital laboratories further classified into in-house labs and outsourced services; these distinctions affect procurement cycles, quality control expectations, and data integration needs. Sample type considerations cover blood, bronchoalveolar lavage, nasopharyngeal swabs, and sputum, driving upstream logistics for collection, transport, and pre-analytic handling. Distribution channel dynamics involve direct sales, distributors, and online channels, which require tailored commercial models and regulatory navigation.

Collectively, these segmentation layers inform targeted product design, commercialization plans, and clinical pathways. Manufacturers and service providers that map solutions to specific segment needs-such as rapid molecular tests optimized for point-of-care settings or robust culture platforms suited to reference laboratories-will be better positioned to address heterogenous clinical workflows and procurement preferences.

Comparative regional perspectives highlighting how diverse healthcare infrastructures, regulatory regimes, and manufacturing capabilities influence pneumonia diagnostics adoption and deployment

Regional dynamics reveal differentiated demand drivers, infrastructure capacities, and policy environments that shape diagnostic strategy and investment priorities. The Americas region combines advanced laboratory networks with significant point-of-care adoption in outpatient and community settings, creating strong demand for rapid molecular and immunoassay solutions that support antimicrobial stewardship and emergency care workflows. In contrast, Europe, Middle East & Africa presents a more heterogeneous landscape where high-capacity tertiary centers coexist with resource-constrained settings; this dichotomy elevates the importance of modular platforms and scalable imaging solutions that can be deployed across diverse care settings while meeting stringent regulatory standards.

Asia-Pacific exhibits high innovation uptake and rapid diffusion of digital health technologies, driven by large patient volumes, expanding private healthcare sectors, and growing regional manufacturing capabilities. These factors encourage the development of cost-effective assays and locally optimized supply chains. Across all regions, however, common themes emerge: a focus on reducing diagnostic turnaround time, improving interoperability of laboratory and radiology data, and strengthening supply chain resilience through regional partnerships. Policy and reimbursement frameworks continue to be pivotal in determining adoption speed and investment levels, and stakeholders that tailor strategies to regional regulatory and operational realities will achieve more sustainable implementation and scale.

Understanding these regional nuances is essential for aligning commercial strategies, clinical validation efforts, and manufacturing footprints to ensure durable adoption and reliable service delivery across global markets.

Insightful analysis of industry strategies showing how product modularity, partner validation, and channel diversity are defining competitive advantage in diagnostics

Industry participants demonstrate a spectrum of strategic approaches that reflect priorities across innovation, scale, and service delivery. Leading diagnostic developers prioritize platform modularity to enable use across point-of-care settings, centralized laboratories, and reference networks, while others focus on highly specialized assays that address pathogen-specific or resistance-detection niches. Partnerships between device firms and clinical laboratory networks have become more common as a means to accelerate clinical validation and to embed new technologies within established workflows.

Commercial strategies also vary by channel orientation: some companies double down on direct sales and laboratory service models to maintain tight control over quality and customer engagement, whereas others leverage distributor networks and digital marketplaces to extend reach and streamline procurement for decentralized customers. In parallel, several firms are exploring companion digital tools and analytics services to enhance diagnostic interpretation, monitor performance in real time, and offer value-added support to clinicians and lab managers.

Ultimately, competitive differentiation is being shaped by the ability to integrate diagnostics into clinical decision pathways, ensure robust supply chain continuity, and deliver scalable customer support. Organizations that balance technological excellence with pragmatic deployment models and thoughtful channel strategies are best positioned to capture sustainable adoption across care settings.

Actionable recommendations for leaders to enhance interoperability, secure regional supply chains, and tailor commercialization for diverse clinical and distribution environments

To translate insights into operational advantage, industry leaders should pursue targeted initiatives that strengthen diagnostic reliability, speed adoption, and enhance supply chain agility. First, prioritize platform interoperability and standardized data formats to ensure that test results and imaging outputs can be integrated seamlessly into electronic health records and clinical decision support tools. This interoperability reduces friction in clinician workflows and supports downstream analytics for quality improvement and surveillance.

Second, invest in regional manufacturing partnerships and multi-sourcing strategies to minimize exposure to trade disruptions and tariff-related cost shifts. Establishing near-shore assembly or contracted production arrangements can shorten lead times and improve responsiveness to demand fluctuations. Third, tailor commercialization models to end-user contexts: emphasize ease-of-use and rapid turnaround for point-of-care deployments, robustness and throughput for hospital and reference laboratories, and home-use-friendly interfaces for remote care settings. Fourth, strengthen clinical evidence generation by designing validation studies that reflect real-world sample diversity, including blood, bronchoalveolar lavage, nasopharyngeal swabs, and sputum, to support broader clinical acceptance.

Finally, develop flexible distribution strategies that combine direct sales for high-touch customers, distributor partnerships for geographic reach, and online channels for convenience. Executing these recommendations will help organizations accelerate adoption, mitigate operational risk, and deliver measurable clinical and economic value to healthcare partners.

A rigorous mixed-methods research approach combining frontline clinical interviews, technical validation review, and supply chain mapping to ensure defensible and actionable findings

The research methodology underpinning this analysis employed a mixed-methods approach to ensure robust, triangulated insights. Primary research included structured interviews with clinical laboratory directors, hospital procurement officers, radiology leaders, and point-of-care clinicians to capture operational priorities and real-world workflow constraints. These qualitative inputs were complemented by technical consultations with assay developers and manufacturing leaders to elucidate platform capabilities, regulatory pathways, and production considerations.

Secondary research involved systematic review of peer-reviewed clinical literature, regulatory guidance documents, and technical performance summaries from manufacturers, with particular attention to analytical sensitivity, specificity, and operational requirements of different technologies. The analysis also incorporated supply chain mapping exercises to identify key nodes susceptible to disruption and to assess the implications of tariff changes on procurement and distribution models.

Data validation was performed through cross-referencing stakeholder interviews with published clinical validation studies and regulatory filings to ensure consistency. Wherever feasible, findings were stress-tested against alternative scenarios to evaluate resilience under varying operational constraints. The resulting methodology balances empirical evidence with practitioner insight to yield a pragmatic and defensible assessment of the pneumonia diagnostics landscape.

Concluding synthesis emphasizing integrated diagnostic strategies, supply chain resilience, and alignment with diverse clinical workflows to improve patient outcomes

In conclusion, the pneumonia diagnostics ecosystem is evolving toward more integrated, flexible, and resilient models that align technological capability with clinical need. Molecular and immunoassay platforms are increasingly available in formats that support decentralized testing, while radiological innovations continue to enhance diagnostic clarity and triage decisions. At the same time, supply chain and policy developments underscore the need for diversified sourcing and regional manufacturing strategies to sustain reliable access to critical consumables and platforms.

For stakeholders across the value chain, the imperative is to align product design, evidence generation, and commercial models with the nuanced requirements of different user segments. Whether serving point-of-care clinicians, hospital laboratories, reference centers, or home-based care, solutions that prioritize interoperability, ease of use, and validated performance across diverse sample types will achieve more durable clinical adoption. By adopting the strategic and operational recommendations outlined earlier, organizations can better navigate trade policy dynamics, accelerate deployment of effective diagnostics, and ultimately contribute to improved patient outcomes.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Pneumonia Testing Market, by Test Type

  • 8.1. Culture
    • 8.1.1. Bacterial Culture
    • 8.1.2. Fungal Culture
  • 8.2. Immunoassay Test
    • 8.2.1. Antibody Test
    • 8.2.2. Antigen Test
  • 8.3. Molecular Test
  • 8.4. Radiological Imaging
    • 8.4.1. CT Scan
    • 8.4.2. X Ray

9. Pneumonia Testing Market, by Technology Platform

  • 9.1. Digital Radiography
  • 9.2. Isothermal Amplification
  • 9.3. Lateral Flow Assay
  • 9.4. RT PCR

10. Pneumonia Testing Market, by Sample Type

  • 10.1. Blood
  • 10.2. Bronchoalveolar Lavage
  • 10.3. Nasopharyngeal Swab
  • 10.4. Sputum

11. Pneumonia Testing Market, by End User

  • 11.1. Home Care
  • 11.2. Hospital Laboratory
    • 11.2.1. In House Lab
    • 11.2.2. Outsourced Services
  • 11.3. Point Of Care Testing
  • 11.4. Reference Laboratory

12. Pneumonia Testing Market, by Distribution Channel

  • 12.1. Offline
  • 12.2. Online

13. Pneumonia Testing Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Pneumonia Testing Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Pneumonia Testing Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Pneumonia Testing Market

17. China Pneumonia Testing Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Abbott Laboratories
  • 18.6. Becton Dickinson and Company
  • 18.7. bioMerieux SA
  • 18.8. Danaher Corporation
  • 18.9. Eurofins Scientific SE
  • 18.10. F. Hoffmann-La Roche Ltd
  • 18.11. Hain Lifescience GmbH by Bruker Corporation
  • 18.12. Hologic, Inc.
  • 18.13. Intec Products, Inc.
  • 18.14. PerkinElmer, Inc.
  • 18.15. Qiagen N.V.
  • 18.16. Siemens Healthineers AG
  • 18.17. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL PNEUMONIA TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL PNEUMONIA TESTING MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL PNEUMONIA TESTING MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL PNEUMONIA TESTING MARKET SIZE, BY TEST TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL PNEUMONIA TESTING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL PNEUMONIA TESTING MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL PNEUMONIA TESTING MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL PNEUMONIA TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL PNEUMONIA TESTING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL PNEUMONIA TESTING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL PNEUMONIA TESTING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES PNEUMONIA TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA PNEUMONIA TESTING MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL PNEUMONIA TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL PNEUMONIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL PNEUMONIA TESTING MARKET SIZE, BY CULTURE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL PNEUMONIA TESTING MARKET SIZE, BY CULTURE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL PNEUMONIA TESTING MARKET SIZE, BY CULTURE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL PNEUMONIA TESTING MARKET SIZE, BY CULTURE, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL PNEUMONIA TESTING MARKET SIZE, BY BACTERIAL CULTURE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL PNEUMONIA TESTING MARKET SIZE, BY BACTERIAL CULTURE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL PNEUMONIA TESTING MARKET SIZE, BY BACTERIAL CULTURE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL PNEUMONIA TESTING MARKET SIZE, BY FUNGAL CULTURE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL PNEUMONIA TESTING MARKET SIZE, BY FUNGAL CULTURE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL PNEUMONIA TESTING MARKET SIZE, BY FUNGAL CULTURE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL PNEUMONIA TESTING MARKET SIZE, BY IMMUNOASSAY TEST, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL PNEUMONIA TESTING MARKET SIZE, BY IMMUNOASSAY TEST, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL PNEUMONIA TESTING MARKET SIZE, BY IMMUNOASSAY TEST, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL PNEUMONIA TESTING MARKET SIZE, BY IMMUNOASSAY TEST, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL PNEUMONIA TESTING MARKET SIZE, BY ANTIBODY TEST, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL PNEUMONIA TESTING MARKET SIZE, BY ANTIBODY TEST, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL PNEUMONIA TESTING MARKET SIZE, BY ANTIBODY TEST, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL PNEUMONIA TESTING MARKET SIZE, BY ANTIGEN TEST, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL PNEUMONIA TESTING MARKET SIZE, BY ANTIGEN TEST, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL PNEUMONIA TESTING MARKET SIZE, BY ANTIGEN TEST, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL PNEUMONIA TESTING MARKET SIZE, BY MOLECULAR TEST, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL PNEUMONIA TESTING MARKET SIZE, BY MOLECULAR TEST, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL PNEUMONIA TESTING MARKET SIZE, BY MOLECULAR TEST, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL PNEUMONIA TESTING MARKET SIZE, BY RADIOLOGICAL IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL PNEUMONIA TESTING MARKET SIZE, BY RADIOLOGICAL IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL PNEUMONIA TESTING MARKET SIZE, BY RADIOLOGICAL IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL PNEUMONIA TESTING MARKET SIZE, BY RADIOLOGICAL IMAGING, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL PNEUMONIA TESTING MARKET SIZE, BY CT SCAN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL PNEUMONIA TESTING MARKET SIZE, BY CT SCAN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL PNEUMONIA TESTING MARKET SIZE, BY CT SCAN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL PNEUMONIA TESTING MARKET SIZE, BY X RAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL PNEUMONIA TESTING MARKET SIZE, BY X RAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL PNEUMONIA TESTING MARKET SIZE, BY X RAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL PNEUMONIA TESTING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL PNEUMONIA TESTING MARKET SIZE, BY DIGITAL RADIOGRAPHY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL PNEUMONIA TESTING MARKET SIZE, BY DIGITAL RADIOGRAPHY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL PNEUMONIA TESTING MARKET SIZE, BY DIGITAL RADIOGRAPHY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL PNEUMONIA TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL PNEUMONIA TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL PNEUMONIA TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL PNEUMONIA TESTING MARKET SIZE, BY LATERAL FLOW ASSAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL PNEUMONIA TESTING MARKET SIZE, BY LATERAL FLOW ASSAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL PNEUMONIA TESTING MARKET SIZE, BY LATERAL FLOW ASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL PNEUMONIA TESTING MARKET SIZE, BY RT PCR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL PNEUMONIA TESTING MARKET SIZE, BY RT PCR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL PNEUMONIA TESTING MARKET SIZE, BY RT PCR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL PNEUMONIA TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL PNEUMONIA TESTING MARKET SIZE, BY BLOOD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL PNEUMONIA TESTING MARKET SIZE, BY BLOOD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL PNEUMONIA TESTING MARKET SIZE, BY BLOOD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL PNEUMONIA TESTING MARKET SIZE, BY BRONCHOALVEOLAR LAVAGE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL PNEUMONIA TESTING MARKET SIZE, BY BRONCHOALVEOLAR LAVAGE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL PNEUMONIA TESTING MARKET SIZE, BY BRONCHOALVEOLAR LAVAGE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL PNEUMONIA TESTING MARKET SIZE, BY NASOPHARYNGEAL SWAB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL PNEUMONIA TESTING MARKET SIZE, BY NASOPHARYNGEAL SWAB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL PNEUMONIA TESTING MARKET SIZE, BY NASOPHARYNGEAL SWAB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL PNEUMONIA TESTING MARKET SIZE, BY SPUTUM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL PNEUMONIA TESTING MARKET SIZE, BY SPUTUM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL PNEUMONIA TESTING MARKET SIZE, BY SPUTUM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL PNEUMONIA TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL PNEUMONIA TESTING MARKET SIZE, BY HOME CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL PNEUMONIA TESTING MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL PNEUMONIA TESTING MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL PNEUMONIA TESTING MARKET SIZE, BY HOSPITAL LABORATORY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL PNEUMONIA TESTING MARKET SIZE, BY HOSPITAL LABORATORY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL PNEUMONIA TESTING MARKET SIZE, BY HOSPITAL LABORATORY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL PNEUMONIA TESTING MARKET SIZE, BY HOSPITAL LABORATORY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL PNEUMONIA TESTING MARKET SIZE, BY IN HOUSE LAB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL PNEUMONIA TESTING MARKET SIZE, BY IN HOUSE LAB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL PNEUMONIA TESTING MARKET SIZE, BY IN HOUSE LAB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL PNEUMONIA TESTING MARKET SIZE, BY OUTSOURCED SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL PNEUMONIA TESTING MARKET SIZE, BY OUTSOURCED SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL PNEUMONIA TESTING MARKET SIZE, BY OUTSOURCED SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL PNEUMONIA TESTING MARKET SIZE, BY POINT OF CARE TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL PNEUMONIA TESTING MARKET SIZE, BY POINT OF CARE TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL PNEUMONIA TESTING MARKET SIZE, BY POINT OF CARE TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL PNEUMONIA TESTING MARKET SIZE, BY REFERENCE LABORATORY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL PNEUMONIA TESTING MARKET SIZE, BY REFERENCE LABORATORY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL PNEUMONIA TESTING MARKET SIZE, BY REFERENCE LABORATORY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL PNEUMONIA TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL PNEUMONIA TESTING MARKET SIZE, BY OFFLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL PNEUMONIA TESTING MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL PNEUMONIA TESTING MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL PNEUMONIA TESTING MARKET SIZE, BY ONLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL PNEUMONIA TESTING MARKET SIZE, BY ONLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL PNEUMONIA TESTING MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL PNEUMONIA TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. AMERICAS PNEUMONIA TESTING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 91. AMERICAS PNEUMONIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 92. AMERICAS PNEUMONIA TESTING MARKET SIZE, BY CULTURE, 2018-2032 (USD MILLION)
  • TABLE 93. AMERICAS PNEUMONIA TESTING MARKET SIZE, BY IMMUNOASSAY TEST, 2018-2032 (USD MILLION)
  • TABLE 94. AMERICAS PNEUMONIA TESTING MARKET SIZE, BY RADIOLOGICAL IMAGING, 2018-2032 (USD MILLION)
  • TABLE 95. AMERICAS PNEUMONIA TESTING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 96. AMERICAS PNEUMONIA TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 97. AMERICAS PNEUMONIA TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 98. AMERICAS PNEUMONIA TESTING MARKET SIZE, BY HOSPITAL LABORATORY, 2018-2032 (USD MILLION)
  • TABLE 99. AMERICAS PNEUMONIA TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 100. NORTH AMERICA PNEUMONIA TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. NORTH AMERICA PNEUMONIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 102. NORTH AMERICA PNEUMONIA TESTING MARKET SIZE, BY CULTURE, 2018-2032 (USD MILLION)
  • TABLE 103. NORTH AMERICA PNEUMONIA TESTING MARKET SIZE, BY IMMUNOASSAY TEST, 2018-2032 (USD MILLION)
  • TABLE 104. NORTH AMERICA PNEUMONIA TESTING MARKET SIZE, BY RADIOLOGICAL IMAGING, 2018-2032 (USD MILLION)
  • TABLE 105. NORTH AMERICA PNEUMONIA TESTING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 106. NORTH AMERICA PNEUMONIA TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 107. NORTH AMERICA PNEUMONIA TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 108. NORTH AMERICA PNEUMONIA TESTING MARKET SIZE, BY HOSPITAL LABORATORY, 2018-2032 (USD MILLION)
  • TABLE 109. NORTH AMERICA PNEUMONIA TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 110. LATIN AMERICA PNEUMONIA TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. LATIN AMERICA PNEUMONIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 112. LATIN AMERICA PNEUMONIA TESTING MARKET SIZE, BY CULTURE, 2018-2032 (USD MILLION)
  • TABLE 113. LATIN AMERICA PNEUMONIA TESTING MARKET SIZE, BY IMMUNOASSAY TEST, 2018-2032 (USD MILLION)
  • TABLE 114. LATIN AMERICA PNEUMONIA TESTING MARKET SIZE, BY RADIOLOGICAL IMAGING, 2018-2032 (USD MILLION)
  • TABLE 115. LATIN AMERICA PNEUMONIA TESTING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 116. LATIN AMERICA PNEUMONIA TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 117. LATIN AMERICA PNEUMONIA TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 118. LATIN AMERICA PNEUMONIA TESTING MARKET SIZE, BY HOSPITAL LABORATORY, 2018-2032 (USD MILLION)
  • TABLE 119. LATIN AMERICA PNEUMONIA TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE, MIDDLE EAST & AFRICA PNEUMONIA TESTING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE, MIDDLE EAST & AFRICA PNEUMONIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE, MIDDLE EAST & AFRICA PNEUMONIA TESTING MARKET SIZE, BY CULTURE, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE, MIDDLE EAST & AFRICA PNEUMONIA TESTING MARKET SIZE, BY IMMUNOASSAY TEST, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE, MIDDLE EAST & AFRICA PNEUMONIA TESTING MARKET SIZE, BY RADIOLOGICAL IMAGING, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA PNEUMONIA TESTING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA PNEUMONIA TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA PNEUMONIA TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA PNEUMONIA TESTING MARKET SIZE, BY HOSPITAL LABORATORY, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA PNEUMONIA TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE PNEUMONIA TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE PNEUMONIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE PNEUMONIA TESTING MARKET SIZE, BY CULTURE, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE PNEUMONIA TESTING MARKET SIZE, BY IMMUNOASSAY TEST, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE PNEUMONIA TESTING MARKET SIZE, BY RADIOLOGICAL IMAGING, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE PNEUMONIA TESTING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE PNEUMONIA TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE PNEUMONIA TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE PNEUMONIA TESTING MARKET SIZE, BY HOSPITAL LABORATORY, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE PNEUMONIA TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 140. MIDDLE EAST PNEUMONIA TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. MIDDLE EAST PNEUMONIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. MIDDLE EAST PNEUMONIA TESTING MARKET SIZE, BY CULTURE, 2018-2032 (USD MILLION)
  • TABLE 143. MIDDLE EAST PNEUMONIA TESTING MARKET SIZE, BY IMMUNOASSAY TEST, 2018-2032 (USD MILLION)
  • TABLE 144. MIDDLE EAST PNEUMONIA TESTING MARKET SIZE, BY RADIOLOGICAL IMAGING, 2018-2032 (USD MILLION)
  • TABLE 145. MIDDLE EAST PNEUMONIA TESTING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 146. MIDDLE EAST PNEUMONIA TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 147. MIDDLE EAST PNEUMONIA TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 148. MIDDLE EAST PNEUMONIA TESTING MARKET SIZE, BY HOSPITAL LABORATORY, 2018-2032 (USD MILLION)
  • TABLE 149. MIDDLE EAST PNEUMONIA TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 150. AFRICA PNEUMONIA TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 151. AFRICA PNEUMONIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 152. AFRICA PNEUMONIA TESTING MARKET SIZE, BY CULTURE, 2018-2032 (USD MILLION)
  • TABLE 153. AFRICA PNEUMONIA TESTING MARKET SIZE, BY IMMUNOASSAY TEST, 2018-2032 (USD MILLION)
  • TABLE 154. AFRICA PNEUMONIA TESTING MARKET SIZE, BY RADIOLOGICAL IMAGING, 2018-2032 (USD MILLION)
  • TABLE 155. AFRICA PNEUMONIA TESTING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 156. AFRICA PNEUMONIA TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. AFRICA PNEUMONIA TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 158. AFRICA PNEUMONIA TESTING MARKET SIZE, BY HOSPITAL LABORATORY, 2018-2032 (USD MILLION)
  • TABLE 159. AFRICA PNEUMONIA TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 160. ASIA-PACIFIC PNEUMONIA TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 161. ASIA-PACIFIC PNEUMONIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 162. ASIA-PACIFIC PNEUMONIA TESTING MARKET SIZE, BY CULTURE, 2018-2032 (USD MILLION)
  • TABLE 163. ASIA-PACIFIC PNEUMONIA TESTING MARKET SIZE, BY IMMUNOASSAY TEST, 2018-2032 (USD MILLION)
  • TABLE 164. ASIA-PACIFIC PNEUMONIA TESTING MARKET SIZE, BY RADIOLOGICAL IMAGING, 2018-2032 (USD MILLION)
  • TABLE 165. ASIA-PACIFIC PNEUMONIA TESTING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 166. ASIA-PACIFIC PNEUMONIA TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 167. ASIA-PACIFIC PNEUMONIA TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 168. ASIA-PACIFIC PNEUMONIA TESTING MARKET SIZE, BY HOSPITAL LABORATORY, 2018-2032 (USD MILLION)
  • TABLE 169. ASIA-PACIFIC PNEUMONIA TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 170. GLOBAL PNEUMONIA TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 171. ASEAN PNEUMONIA TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. ASEAN PNEUMONIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. ASEAN PNEUMONIA TESTING MARKET SIZE, BY CULTURE, 2018-2032 (USD MILLION)
  • TABLE 174. ASEAN PNEUMONIA TESTING MARKET SIZE, BY IMMUNOASSAY TEST, 2018-2032 (USD MILLION)
  • TABLE 175. ASEAN PNEUMONIA TESTING MARKET SIZE, BY RADIOLOGICAL IMAGING, 2018-2032 (USD MILLION)
  • TABLE 176. ASEAN PNEUMONIA TESTING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 177. ASEAN PNEUMONIA TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 178. ASEAN PNEUMONIA TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 179. ASEAN PNEUMONIA TESTING MARKET SIZE, BY HOSPITAL LABORATORY, 2018-2032 (USD MILLION)
  • TABLE 180. ASEAN PNEUMONIA TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 181. GCC PNEUMONIA TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 182. GCC PNEUMONIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 183. GCC PNEUMONIA TESTING MARKET SIZE, BY CULTURE, 2018-2032 (USD MILLION)
  • TABLE 184. GCC PNEUMONIA TESTING MARKET SIZE, BY IMMUNOASSAY TEST, 2018-2032 (USD MILLION)
  • TABLE 185. GCC PNEUMONIA TESTING MARKET SIZE, BY RADIOLOGICAL IMAGING, 2018-2032 (USD MILLION)
  • TABLE 186. GCC PNEUMONIA TESTING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 187. GCC PNEUMONIA TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 188. GCC PNEUMONIA TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 189. GCC PNEUMONIA TESTING MARKET SIZE, BY HOSPITAL LABORATORY, 2018-2032 (USD MILLION)
  • TABLE 190. GCC PNEUMONIA TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPEAN UNION PNEUMONIA TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPEAN UNION PNEUMONIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPEAN UNION PNEUMONIA TESTING MARKET SIZE, BY CULTURE, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPEAN UNION PNEUMONIA TESTING MARKET SIZE, BY IMMUNOASSAY TEST, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPEAN UNION PNEUMONIA TESTING MARKET SIZE, BY RADIOLOGICAL IMAGING, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPEAN UNION PNEUMONIA TESTING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPEAN UNION PNEUMONIA TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPEAN UNION PNEUMONIA TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPEAN UNION PNEUMONIA TESTING MARKET SIZE, BY HOSPITAL LABORATORY, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPEAN UNION PNEUMONIA TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 201. BRICS PNEUMONIA TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 202. BRICS PNEUMONIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 203. BRICS PNEUMONIA TESTING MARKET SIZE, BY CULTURE, 2018-2032 (USD MILLION)
  • TABLE 204. BRICS PNEUMONIA TESTING MARKET SIZE, BY IMMUNOASSAY TEST, 2018-2032 (USD MILLION)
  • TABLE 205. BRICS PNEUMONIA TESTING MARKET SIZE, BY RADIOLOGICAL IMAGING, 2018-2032 (USD MILLION)
  • TABLE 206. BRICS PNEUMONIA TESTING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 207. BRICS PNEUMONIA TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 208. BRICS PNEUMONIA TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 209. BRICS PNEUMONIA TESTING MARKET SIZE, BY HOSPITAL LABORATORY, 2018-2032 (USD MILLION)
  • TABLE 210. BRICS PNEUMONIA TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 211. G7 PNEUMONIA TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 212. G7 PNEUMONIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 213. G7 PNEUMONIA TESTING MARKET SIZE, BY CULTURE, 2018-2032 (USD MILLION)
  • TABLE 214. G7 PNEUMONIA TESTING MARKET SIZE, BY IMMUNOASSAY TEST, 2018-2032 (USD MILLION)
  • TABLE 215. G7 PNEUMONIA TESTING MARKET SIZE, BY RADIOLOGICAL IMAGING, 2018-2032 (USD MILLION)
  • TABLE 216. G7 PNEUMONIA TESTING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 217. G7 PNEUMONIA TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 218. G7 PNEUMONIA TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 219. G7 PNEUMONIA TESTING MARKET SIZE, BY HOSPITAL LABORATORY, 2018-2032 (USD MILLION)
  • TABLE 220. G7 PNEUMONIA TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 221. NATO PNEUMONIA TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 222. NATO PNEUMONIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 223. NATO PNEUMONIA TESTING MARKET SIZE, BY CULTURE, 2018-2032 (USD MILLION)
  • TABLE 224. NATO PNEUMONIA TESTING MARKET SIZE, BY IMMUNOASSAY TEST, 2018-2032 (USD MILLION)
  • TABLE 225. NATO PNEUMONIA TESTING MARKET SIZE, BY RADIOLOGICAL IMAGING, 2018-2032 (USD MILLION)
  • TABLE 226. NATO PNEUMONIA TESTING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 227. NATO PNEUMONIA TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 228. NATO PNEUMONIA TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 229. NATO PNEUMONIA TESTING MARKET SIZE, BY HOSPITAL LABORATORY, 2018-2032 (USD MILLION)
  • TABLE 230. NATO PNEUMONIA TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 231. GLOBAL PNEUMONIA TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 232. UNITED STATES PNEUMONIA TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 233. UNITED STATES PNEUMONIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 234. UNITED STATES PNEUMONIA TESTING MARKET SIZE, BY CULTURE, 2018-2032 (USD MILLION)
  • TABLE 235. UNITED STATES PNEUMONIA TESTING MARKET SIZE, BY IMMUNOASSAY TEST, 2018-2032 (USD MILLION)
  • TABLE 236. UNITED STATES PNEUMONIA TESTING MARKET SIZE, BY RADIOLOGICAL IMAGING, 2018-2032 (USD MILLION)
  • TABLE 237. UNITED STATES PNEUMONIA TESTING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 238. UNITED STATES PNEUMONIA TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 239. UNITED STATES PNEUMONIA TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 240. UNITED STATES PNEUMONIA TESTING MARKET SIZE, BY HOSPITAL LABORATORY, 2018-2032 (USD MILLION)
  • TABLE 241. UNITED STATES PNEUMONIA TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 242. CHINA PNEUMONIA TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 243. CHINA PNEUMONIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 244. CHINA PNEUMONIA TESTING MARKET SIZE, BY CULTURE, 2018-2032 (USD MILLION)
  • TABLE 245. CHINA PNEUMONIA TESTING MARKET SIZE, BY IMMUNOASSAY TEST, 2018-2032 (USD MILLION)
  • TABLE 246. CHINA PNEUMONIA TESTING MARKET SIZE, BY RADIOLOGICAL IMAGING, 2018-2032 (USD MILLION)
  • TABLE 247. CHINA PNEUMONIA TESTING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 248. CHINA PNEUMONIA TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 249. CHINA PNEUMONIA TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 250. CHINA PNEUMONIA TESTING MARKET SIZE, BY HOSPITAL LABORATORY, 2018-2032 (USD MILLION)
  • TABLE 251. CHINA PNEUMONIA TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)